BTEC.SW iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) USD
- Total assets
- 445M
- Expense ratio
- 0.34%
- Dividend yield
- -
- 1-year return
- +33.42%
- Holdings
- 247
- Since
- 2017
Fund data as reported by the issuer, updated Oct 28, 2026. Total assets are in the fund's base currency.
What does BTEC.SW invest in?
Tracks Morningstar Gbl Biotechnology NR USD- Mostly US stocks (96.8%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (95.8%)
- Top 3 holdings: 24.6% of the fund
Asset allocation
- US stocks 96.8%
- Non-US stocks 4.9%
- Cash 0.2%
Top holdings
- Gilead Sciences Inc 8.78%
- Amgen Inc 8.17%
- Vertex Pharmaceuticals Inc 7.65%
- Regeneron Pharmaceuticals Inc 5.43%
- Moderna Inc 5.35%
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) USD performance
Sharpe ratio 0.99- This year
- +24.91%
- 1 year
- +33.42%
- 3 years
- +24.26%
- 5 years
- +8.14%
Volatility 17.2% over 1 year and 17.7% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
BTEC.SW price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) USD
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.
Full fund profileiShares Nasdaq US Biotechnology UCITS ETF USD (Acc) USD top holdings
47.1% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Gilead Sciences Inc GILD.US | Healthcare | United States | 8.78% |
| Amgen Inc AMGN.US | Healthcare | United States | 8.17% |
| Vertex Pharmaceuticals Inc VRTX.US | Healthcare | United States | 7.65% |
| Regeneron Pharmaceuticals Inc REGN.US | Healthcare | United States | 5.43% |
| Moderna Inc MRNA.US | Healthcare | United States | 5.35% |
| Illumina Inc ILMN.US | Healthcare | United States | 2.85% |
| Revolution Medicines Inc RVMD.US | Healthcare | United States | 2.52% |
| Biogen Inc BIIB.US | Healthcare | United States | 2.48% |
| Alnylam Pharmaceuticals Inc ALNY.US | Healthcare | United States | 2.00% |
| Royalty Pharma Plc RPRX.US | Healthcare | United States | 1.83% |
The 10 largest of 247 holdings.
BTEC.SW sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
BTEC.SW regional exposure
- North America95.8%
- Europe Developed2.1%
- United Kingdom1.9%
- Asia Emerging0.1%
- Australasia0.0%
- Africa/Middle East0.0%
- Asia Developed0.0%
Share of the stocks in the fund.
Company size
Average market cap 26.8B- Mega cap0.6%
- Big cap27.2%
- Medium cap33.0%
- Small cap26.5%
- Micro cap11.1%
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) USD fund profile
- Fund name
- iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) USD
- Ticker
- BTEC.SW
- Exchange
- SIX Swiss Exchange
- Index tracked
- Morningstar Gbl Biotechnology NR USD
- Category
- Healthcare Equity
- Domicile
- Ireland
- Inception date
- Oct 19, 2017
- Trading currency
- USD
- Expense ratio
- 0.34%
About iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) USD
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.